CA2653017A1 - Formulations a liberation prolongee et stable d'oxymorphone et leurs procedes d'utilisation - Google Patents
Formulations a liberation prolongee et stable d'oxymorphone et leurs procedes d'utilisation Download PDFInfo
- Publication number
- CA2653017A1 CA2653017A1 CA002653017A CA2653017A CA2653017A1 CA 2653017 A1 CA2653017 A1 CA 2653017A1 CA 002653017 A CA002653017 A CA 002653017A CA 2653017 A CA2653017 A CA 2653017A CA 2653017 A1 CA2653017 A1 CA 2653017A1
- Authority
- CA
- Canada
- Prior art keywords
- oxymorphone
- formulation
- blood concentration
- sustained release
- maximum blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 title claims abstract 71
- 229960005118 oxymorphone Drugs 0.000 title claims abstract 71
- 238000009472 formulation Methods 0.000 title claims abstract 61
- 239000000203 mixture Substances 0.000 title claims abstract 61
- 238000000034 method Methods 0.000 title claims abstract 47
- 238000013268 sustained release Methods 0.000 title claims abstract 26
- 239000012730 sustained-release form Substances 0.000 title claims abstract 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 23
- 239000007909 solid dosage form Substances 0.000 claims abstract 8
- 230000036407 pain Effects 0.000 claims abstract 6
- 239000008280 blood Substances 0.000 claims 30
- 210000004369 blood Anatomy 0.000 claims 30
- 230000036592 analgesia Effects 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/039781 WO2008045047A1 (fr) | 2006-10-10 | 2006-10-10 | Formulations à libération prolongée et stable d'oxymorphone et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2653017A1 true CA2653017A1 (fr) | 2008-04-17 |
Family
ID=38134325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002653017A Abandoned CA2653017A1 (fr) | 2006-10-10 | 2006-10-10 | Formulations a liberation prolongee et stable d'oxymorphone et leurs procedes d'utilisation |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2097070A1 (fr) |
| JP (1) | JP2010505948A (fr) |
| CN (1) | CN101578094A (fr) |
| AU (1) | AU2006349472A1 (fr) |
| BR (1) | BRPI0621951A2 (fr) |
| CA (1) | CA2653017A1 (fr) |
| IL (1) | IL198170A0 (fr) |
| MX (1) | MX2009003770A (fr) |
| WO (1) | WO2008045047A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551770A (zh) | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| EP2097069A1 (fr) * | 2006-10-10 | 2009-09-09 | Penwest Pharmaceuticals Co. | Formulations d'oxymorphone robustes à libération prolongée |
| CN104622791A (zh) * | 2015-02-13 | 2015-05-20 | 扬子江药业集团有限公司 | 地佐辛口服制剂 |
| EP3473246A1 (fr) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Formulations anti-abus à libération immédiate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551770A (zh) * | 2001-07-06 | 2004-12-01 | ������ҩ������˾ | 羟吗啡酮控释制剂 |
| BR0205722A (pt) * | 2001-07-06 | 2005-04-05 | Penwest Pharmaceuticals Compan | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor |
| CA2459976A1 (fr) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives |
| EP2097069A1 (fr) * | 2006-10-10 | 2009-09-09 | Penwest Pharmaceuticals Co. | Formulations d'oxymorphone robustes à libération prolongée |
-
2006
- 2006-10-10 JP JP2009532330A patent/JP2010505948A/ja active Pending
- 2006-10-10 CN CNA2006800560350A patent/CN101578094A/zh active Pending
- 2006-10-10 BR BRPI0621951-9A patent/BRPI0621951A2/pt not_active Application Discontinuation
- 2006-10-10 WO PCT/US2006/039781 patent/WO2008045047A1/fr active Application Filing
- 2006-10-10 EP EP06825782A patent/EP2097070A1/fr not_active Withdrawn
- 2006-10-10 CA CA002653017A patent/CA2653017A1/fr not_active Abandoned
- 2006-10-10 MX MX2009003770A patent/MX2009003770A/es not_active Application Discontinuation
- 2006-10-10 AU AU2006349472A patent/AU2006349472A1/en not_active Abandoned
-
2009
- 2009-04-16 IL IL198170A patent/IL198170A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009003770A (es) | 2009-07-22 |
| EP2097070A1 (fr) | 2009-09-09 |
| WO2008045047A1 (fr) | 2008-04-17 |
| BRPI0621951A2 (pt) | 2011-10-18 |
| JP2010505948A (ja) | 2010-02-25 |
| IL198170A0 (en) | 2009-12-24 |
| AU2006349472A1 (en) | 2008-04-17 |
| CN101578094A (zh) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020079277A (ja) | ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス | |
| US20170157255A1 (en) | Compositions and methods for reducing overdose | |
| KR20080109007A (ko) | 우발적 오용 및 불법 전환을 방지하기 위한 내분쇄성 옥시코돈 정제 | |
| US20040126428A1 (en) | Pharmaceutical formulation including a resinate and an aversive agent | |
| MX2009003771A (es) | Formulaciones robustas de liberacion sostenida. | |
| EP1275381A4 (fr) | Compositions solides enrobees a liberation decalee dans le temps | |
| CA2661759A1 (fr) | Cachet de buprenophine comme traitement de substitution lie a la toxicomanie | |
| CA2888278A1 (fr) | Formulations de medicament pour administration par voie orale | |
| MX2008009267A (es) | Forma farmaceutica y metodo para la administracion de farmacos de abuso. | |
| NO338567B1 (no) | Brusende oral doseringsform for opiatet oksycodon, og dets anvendelse som et medikament og ved behandling av smerte | |
| PT1807156T (pt) | Novas formulações farmacêuticas úteis no tratamento de insónia | |
| RU2006137330A (ru) | Пероральные матричные композиции, содержащие ликарбазепин | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| JP2016512247A (ja) | 食事に関係なく投与され得る急速な開始および延長された痛覚消失のためのヒドロコドンおよびアセトアミノフェンを含む延長放出組成物 | |
| CA2653017A1 (fr) | Formulations a liberation prolongee et stable d'oxymorphone et leurs procedes d'utilisation | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| CN107205943A (zh) | 纳洛酮单剂和多层片剂 | |
| WO2012104641A2 (fr) | Formulation pharmaceutique | |
| WO2011128634A2 (fr) | Compositions pharmaceutiques en vente libre | |
| WO2016084099A1 (fr) | Composition de capsule en gélatine souple d'agents antitussifs | |
| KR101697773B1 (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| TW200831072A (en) | Non-steroidal anti-inflammatory drugs for cough | |
| Pande et al. | Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone) | |
| MX2009003772A (es) | Formulaciones de oximorfona robustas, de liberacion sostenida. | |
| CN103432596B (zh) | 新癀片中药成分镇痛作用的机理研究方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150129 |